MX2020004975A - Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia. - Google Patents

Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.

Info

Publication number
MX2020004975A
MX2020004975A MX2020004975A MX2020004975A MX2020004975A MX 2020004975 A MX2020004975 A MX 2020004975A MX 2020004975 A MX2020004975 A MX 2020004975A MX 2020004975 A MX2020004975 A MX 2020004975A MX 2020004975 A MX2020004975 A MX 2020004975A
Authority
MX
Mexico
Prior art keywords
schizophrenia
mitigation
prevention
carbamate compound
treatment
Prior art date
Application number
MX2020004975A
Other languages
English (en)
Inventor
Young Koo Jang
Chan Mi Joung
Ji Won Lee
Sun Gwan Hwang
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2020004975A publication Critical patent/MX2020004975A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a una mezcla para prevención, mitigación, o tratamiento de esquizofrenia, la mezcla que contiene un compuesto de carbamato de la fórmula química 1, o una sal, solvato, o hidrato farmacéuticamente aceptable del mismo y, más específicamente, a una mezcla y una composición farmacéutica cada una que contiene un compuesto de carbamato de la fórmula química 1 y aripiprazol y a un uso de la misma para tratar esquizofrenia.
MX2020004975A 2017-11-14 2018-11-13 Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia. MX2020004975A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170151253 2017-11-14
PCT/KR2018/013769 WO2019098634A1 (ko) 2017-11-14 2018-11-13 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물

Publications (1)

Publication Number Publication Date
MX2020004975A true MX2020004975A (es) 2020-08-24

Family

ID=66539804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004975A MX2020004975A (es) 2017-11-14 2018-11-13 Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.

Country Status (11)

Country Link
US (3) US11116751B2 (es)
EP (1) EP3711759A4 (es)
JP (2) JP7355747B2 (es)
KR (1) KR20200074157A (es)
CN (2) CN111432813B (es)
AU (1) AU2018367733B2 (es)
BR (1) BR112020009310A2 (es)
CA (1) CA3081226A1 (es)
IL (1) IL274437B1 (es)
MX (1) MX2020004975A (es)
WO (1) WO2019098634A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1809620B1 (en) * 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US7598279B2 (en) 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
TW200848041A (en) * 2007-03-30 2008-12-16 Otsuka Pharma Co Ltd A medicament for treating schizophrenia comprising cilostazol
CN102803233B (zh) 2009-06-22 2017-03-01 爱思开生物制药株式会社 制备氨基甲酸(r)‑1‑芳基‑2‑四唑基‑乙酯的方法
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
WO2013131018A1 (en) * 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
RU2610169C2 (ru) * 2014-09-11 2017-02-08 Общество С Ограниченной Ответственностью "Валентек" ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ
CA2961380A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
WO2016065586A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole, triazole and tetrazole orexin receptor antagonists
US9771335B2 (en) 2015-07-31 2017-09-26 The Johns Hopkins University Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels
WO2017066590A1 (en) 2015-10-16 2017-04-20 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
US11221329B2 (en) * 2015-10-30 2022-01-11 Lieber Institute, Inc. Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity
KR20180068493A (ko) * 2016-12-14 2018-06-22 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도
EP4062906A4 (en) * 2019-11-22 2024-01-03 SK Biopharmaceuticals Co., Ltd. ORAL PHARMACEUTICAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND METHOD FOR PREPARING THIS COMPOSITION

Also Published As

Publication number Publication date
BR112020009310A2 (pt) 2020-10-13
IL274437B1 (en) 2024-05-01
RU2020119301A3 (es) 2021-12-15
KR20200074157A (ko) 2020-06-24
IL274437A (en) 2020-06-30
CN111432813B (zh) 2024-01-09
EP3711759A1 (en) 2020-09-23
JP2021503012A (ja) 2021-02-04
EP3711759A4 (en) 2021-11-24
CN111432813A (zh) 2020-07-17
US20210361622A1 (en) 2021-11-25
WO2019098634A1 (ko) 2019-05-23
US20230321041A1 (en) 2023-10-12
JP2023139233A (ja) 2023-10-03
CN117064892A (zh) 2023-11-17
RU2020119301A (ru) 2021-12-15
US11116751B2 (en) 2021-09-14
AU2018367733A1 (en) 2020-05-21
US20200281895A1 (en) 2020-09-10
CA3081226A1 (en) 2019-05-23
US11717509B2 (en) 2023-08-08
AU2018367733B2 (en) 2024-06-20
JP7355747B2 (ja) 2023-10-03

Similar Documents

Publication Publication Date Title
SG11201907038WA (en) Quinazoline compound
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MY194116A (en) Pharmaceutical compounds
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
WO2016100578A3 (en) Antimicrobial polymyxins for treatment of bacterial infections
PH12017501130A1 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2020004975A (es) Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2020008706A (es) Nuevos compuestos de opioides y sus usos.
MX2022001516A (es) Antagonistas del receptor de neuropeptido ff.